PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VIR vs. DNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


VIRDNA
YTD Return-4.57%-87.44%
1Y Return17.94%-83.15%
3Y Return (Ann)-33.47%-75.86%
Sharpe Ratio0.19-0.86
Sortino Ratio0.84-1.94
Omega Ratio1.090.79
Calmar Ratio0.13-0.87
Martin Ratio0.49-1.37
Ulcer Index23.93%62.43%
Daily Std Dev60.95%99.85%
Max Drawdown-91.26%-99.10%
Current Drawdown-88.44%-98.58%

Fundamentals


VIRDNA
Market Cap$1.34B$471.84M
EPS-$3.87-$18.00
Total Revenue (TTM)$78.62M$128.91M
Gross Profit (TTM)$64.40M$59.84M
EBITDA (TTM)-$499.25M-$420.68M

Correlation

-0.50.00.51.00.4

The correlation between VIR and DNA is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

VIR vs. DNA - Performance Comparison

In the year-to-date period, VIR achieves a -4.57% return, which is significantly higher than DNA's -87.44% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%JuneJulyAugustSeptemberOctoberNovember
1.70%
-72.07%
VIR
DNA

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VIR vs. DNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


VIR
Sharpe ratio
The chart of Sharpe ratio for VIR, currently valued at 0.19, compared to the broader market-4.00-2.000.002.004.000.19
Sortino ratio
The chart of Sortino ratio for VIR, currently valued at 0.84, compared to the broader market-4.00-2.000.002.004.006.000.84
Omega ratio
The chart of Omega ratio for VIR, currently valued at 1.09, compared to the broader market0.501.001.502.001.09
Calmar ratio
The chart of Calmar ratio for VIR, currently valued at 0.14, compared to the broader market0.002.004.006.000.14
Martin ratio
The chart of Martin ratio for VIR, currently valued at 0.49, compared to the broader market0.0010.0020.0030.000.49
DNA
Sharpe ratio
The chart of Sharpe ratio for DNA, currently valued at -0.86, compared to the broader market-4.00-2.000.002.004.00-0.86
Sortino ratio
The chart of Sortino ratio for DNA, currently valued at -1.94, compared to the broader market-4.00-2.000.002.004.006.00-1.94
Omega ratio
The chart of Omega ratio for DNA, currently valued at 0.79, compared to the broader market0.501.001.502.000.79
Calmar ratio
The chart of Calmar ratio for DNA, currently valued at -0.87, compared to the broader market0.002.004.006.00-0.87
Martin ratio
The chart of Martin ratio for DNA, currently valued at -1.37, compared to the broader market0.0010.0020.0030.00-1.37

VIR vs. DNA - Sharpe Ratio Comparison

The current VIR Sharpe Ratio is 0.19, which is higher than the DNA Sharpe Ratio of -0.86. The chart below compares the historical Sharpe Ratios of VIR and DNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.000.200.40JuneJulyAugustSeptemberOctoberNovember
0.19
-0.86
VIR
DNA

Dividends

VIR vs. DNA - Dividend Comparison

Neither VIR nor DNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

VIR vs. DNA - Drawdown Comparison

The maximum VIR drawdown since its inception was -91.26%, smaller than the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for VIR and DNA. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%-80.00%JuneJulyAugustSeptemberOctoberNovember
-82.40%
-98.58%
VIR
DNA

Volatility

VIR vs. DNA - Volatility Comparison

Vir Biotechnology, Inc. (VIR) has a higher volatility of 23.41% compared to Ginkgo Bioworks Holdings, Inc. (DNA) at 20.35%. This indicates that VIR's price experiences larger fluctuations and is considered to be riskier than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%JuneJulyAugustSeptemberOctoberNovember
23.41%
20.35%
VIR
DNA

Financials

VIR vs. DNA - Financials Comparison

This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items